Lactobacillus casei PXN 37

Frequently asked

• What is Lactobacillus casei PXN 37 good for according to research?

  Based on 3 studies, Lactobacillus casei PXN 37 has shown beneficial effects on reducing inflammation with moderate effect sizes. Another 3 studies report benefits for improving quality of life, though results were not always statistically significant and effect sizes ranged from small to moderate. The evidence base is small and conclusions should be considered preliminary.
• What dose of Lactobacillus casei PXN 37 is typically used in studies?

  No specific dose, form, or duration data were reported in the available systematic reviews for either reduced inflammation or improved quality of life. Therefore, no recommended dose range can be identified from the current research.
• Who benefits most from Lactobacillus casei PXN 37?

  Research on reduced inflammation has involved patients with autoimmune diseases, depressed patients with somatic comorbidities, and patients with neurodegenerative diseases (Alzheimer's, Parkinson's, multiple sclerosis, mild cognitive impairment). For quality of life, populations included colorectal cancer patients undergoing chemotherapy, neurodegenerative disease patients, and gastrointestinal patients. All studies reported benefits, but the small sample size limits generalizability.
• Are there caveats or limitations in the research on Lactobacillus casei PXN 37?

  Yes, the evidence base is very small, with only 3 studies per outcome. All conclusions are preliminary. The available literature is overwhelmingly positive, which may reflect publication bias where studies with null results are less likely to be published. For quality of life, many individual studies did not reach statistical significance.
• Does Lactobacillus casei PXN 37 help reduce inflammation?

  In all 3 studies available, Lactobacillus casei PXN 37 was associated with reduced inflammation, with moderate effect sizes in 2 studies and a small effect in 1. The populations studied included autoimmune diseases, depression with somatic comorbidities, and neurodegenerative diseases. However, the evidence strength is rated low and should be considered preliminary.
• Does Lactobacillus casei PXN 37 improve quality of life?

  All 3 studies reported beneficial effects of Lactobacillus casei PXN 37 on quality of life in patients with colorectal cancer during chemotherapy, neurodegenerative diseases, and gastrointestinal diseases. However, effect sizes were mixed (small to moderate), many studies did not reach statistical significance, and the evidence is rated very low due to the small number of studies and potential publication bias.